Home Newsfeeds Maxim Group Downgrades Amryt Pharma to Hold

Maxim Group Downgrades Amryt Pharma to Hold

Maxim Group analyst Jason McCarthy downgrades Amryt Pharma (NASDAQ:AMYT) from Buy to Hold.

byBenzinga Newsdesk

January 10, 2023

1 minute read

Maxim Group analyst Jason McCarthy downgrades Amryt Pharma (NASDAQ:AMYT) from Buy to Hold.

Paychex Tops Q1 Consensus; Boosts FY23 EPS Forecast

By Anusuya Lahiri

September 28, 9:59 AM

Paychex, Inc (NASDAQ:PAYX) reported first-quarter FY23 revenue growth of 11% year-on-year to $1.21 billion, beating the consensus of $1.19 billion. Total…

PAYX

AstraZeneca – Daiichi Sankyo’s Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs

By Vandana Singh

December 19, 9:27 AM

The European Commission has approved AstraZeneca Plc (NASDAQ:AZN) – Daiichi Sankyo’s (OTC:DSKYF) (OTC:DSNKY) Enhertu (trastuzumab deruxtecan) for advanced HER2-positive gastric or gastroesophageal junction…

AZN